Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review.
Hum Vaccin Immunother
; 19(2): 2245705, 2023 08 01.
Article
in En
| MEDLINE
| ID: mdl-37642229
ABSTRACT
The four-component meningococcal serogroup B vaccine (4CMenB) is indicated for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B. Co-administering 4CMenB with other vaccines may improve vaccine uptake provided that the safety and immunogenicity of either are not affected. Published literature on the immunogenicity and reactogenicity of 4CMenB co-administered with other routine childhood and adulthood vaccines was reviewed. From 282 publications identified, data were collated from 10 clinical studies, 3 real-world studies, and 3 reviews. The evidence showed that 4CMenB co-administration is not associated with significant safety concerns or clinically relevant immunological interferences. The increased reactogenicity (e.g., fever) associated with 4CMenB co-administration can be adequately managed with prophylactic paracetamol in children. Thus, 4CMenB co-administration has the potential to maximize vaccine coverage and improve protection against IMD globally.
Key words
Full text:
1
Collection:
01-internacional
Health context:
4_TD
Database:
MEDLINE
Main subject:
Meningococcal Vaccines
/
Neisseria meningitidis, Serogroup B
/
Meningococcal Infections
Limits:
Child
/
Humans
Language:
En
Journal:
Hum Vaccin Immunother
Year:
2023
Document type:
Article